Matthew Pink

Company: Biodesix

Job title: Senior Director, Head of Business Development

Seminars:

Sensitivity and Speed Where It Counts: Utility of ddPCR as a Blood Based CDx platform 3:20 pm

•  Without timely and accurate molecular information, drug developers may miss opportunities to accelerate clinical trial enrollment and commercialization. •  Liquid biopsies are proving to be useful complements to tissue-based testing by increasing the likelihood that patients have molecular results prior to treatment initiation and can be considered for both approved targeted therapies and clinical trials.…Read more

day: Day 1 - PM - blue